274 related articles for article (PubMed ID: 16033061)
1. Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.
Waldmann J; Stachs A; Terpe H; Stropahl G; Makovitzky J
Anticancer Res; 2005; 25(3A):1559-65. PubMed ID: 16033061
[TBL] [Abstract][Full Text] [Related]
2. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases.
Lee TK; Miyamoto H; Osunkoya AO; Guo CC; Weiss SW; Epstein JI
Am J Surg Pathol; 2010 Apr; 34(4):502-9. PubMed ID: 20154594
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
5. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
[TBL] [Abstract][Full Text] [Related]
6. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
Ip PP; Cheung AN
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics.
Watanabe K; Suzuki T
Histopathology; 2006 Apr; 48(5):563-8. PubMed ID: 16623782
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of biological potential of smooth muscle tumours.
Miettinen M; Fetsch JF
Histopathology; 2006 Jan; 48(1):97-105. PubMed ID: 16359541
[TBL] [Abstract][Full Text] [Related]
9. Quantitative measurements of desmin and vimentin immunostains and cell density in leiomyomas and leiomyosarcomas.
Remmelink M; Salmon I; Goldschmidt D; Decaestecker C; Nemec E; Berthe JV; Petein M; Pasteels JL; Kiss R
Anal Cell Pathol; 1996 Oct; 12(1):25-44. PubMed ID: 8933907
[TBL] [Abstract][Full Text] [Related]
10. Predictors of malignant behaviour in gastrointestinal stromal tumours: a clinicopathological study of 34 cases.
Abdulkader I; Cameselle-Teijeiro J; Gude F; Fraga M; Varela-DurĂ¡n J; Barreiro F; Forteza J
Eur J Surg; 2002; 168(5):288-96. PubMed ID: 12375611
[TBL] [Abstract][Full Text] [Related]
11. [Histological diagnosis and clinical features in borderline smooth muscle tumors of the uterus].
Shi YF; Xie X; Zhao CL
Zhonghua Fu Chan Ke Za Zhi; 1994 Apr; 29(4):201-4, 251. PubMed ID: 8082439
[TBL] [Abstract][Full Text] [Related]
12. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
Fadare O; Liang SX
Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
[TBL] [Abstract][Full Text] [Related]
13. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
14. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.
Bell SW; Kempson RL; Hendrickson MR
Am J Surg Pathol; 1994 Jun; 18(6):535-58. PubMed ID: 8179071
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
16. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
Leiser AL; Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi DS; Soslow RA
Gynecol Oncol; 2006 Apr; 101(1):86-91. PubMed ID: 16289259
[TBL] [Abstract][Full Text] [Related]
19. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
20. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]